News Quantified

ESPR – esperion therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes

Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results [Yahoo! Finance]

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.

Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.

-4.2%

MISS

-0.6%

BEAT

-5.3%

MISS

12.0%

BEAT

Cantor Fitzgerald

Market Outperform

Market Outperform

Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Koenig Sheldon L.

Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Looker Benjamin

Form 4 Esperion Therapeutics, For: Dec 17 Filed by: Halladay Benjamin

Form 144 Esperion Therapeutics, Filed by: Koenig Sheldon L.

Form 144 Esperion Therapeutics, Filed by: Looker Benjamin

Top News Gainers

3/18 Form 8-K Esperion Therapeutics, For: Mar 14 18.2%

3/17 Esperion Therapeutics Inc (NASDAQ: ESPR) was upgraded by analysts at Citigroup Inc from a "neutral" rating to a "buy" rating. 14.6%

5/5 Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review 11.6%

11/17 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions 10.0%

4/20 Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan 7.2%

1/31 Form 8-K Esperion Therapeutics, For: Jan 31 6.6%

2/12 Form SC 13G/A Esperion Therapeutics, Filed by: VANGUARD GROUP INC 5.9%

2/28 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 5.2%

4/16 Form DEF 14A Esperion Therapeutics, For: May 28 4.6%

3/23 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiol 4.5%

Top News Decliners

2/27 Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results -11.2%

3/12 Form 4 Esperion Therapeutics, For: Mar 11 Filed by: MAYLEBEN TIMOTHY M -10.3%

4/1 Esperion Therapeutics Inc (NASDAQ: ESPR) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a price target on the stock. -9.3%

11/6 Q3/2019 9/30/2019 EPS -2.520 ZacksConsensus -2.010 ActVsEst (0.510) - Miss -8.6%

3/31 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.9%

4/30 Esperion to Report First Quarter 2020 Financial Results May 6, 2020 -7.9%

1/24 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.3%

2/25 Esperion Therapeutics: The Path After FDA Approval [Seeking Alpha] -4.8%

8/30 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.7%

2/14 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. -4.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day